-
Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study
•
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the one-year follow-up results from the multi-center TRAVEL II study for its transjugular tricuspid valve replacement product, LuX-Valve Plus, at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 annual meeting in Washington. The TRAVEL II study, which assesses…
-
Ningbo-Based Jenscare Scientific Announces Successful Follow-up Data for Transjugular Tricuspid Valve Device
•
Jenscare Scientific Co., Ltd (HKG: 9877), a leading manufacturer of structural heart disease devices headquartered in Ningbo, has announced the six-month follow-up results from the multi-center TRAVEL II study for its transjugular tricuspid valve replacement product, LuX-Valve Plus. The TRAVEL II study, a prospective, multi-center, single-arm clinical trial, was designed…
-
Jenscare Scientific’s LuX-Valve Fails to Gain Approval from China’s CDME
•
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that its transcatheter tricuspid valve replacement system, LuX-Valve, did not pass the approval review by China’s Center for Medical Device Evaluation (CDME). The LuX-Valve, which was granted innovative medical device status in China in 2019 and…
-
Jenscare Scientific Completes Enrollment in Clinical Study for Mitral Valve Repair System
•
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in Ningbo, has announced the successful completion of patient enrollment in a confirmatory study for its flagship product, the JensClip transcatheter mitral valve repair and clamping system. The system is designed to address severe mitral regurgitation,…
-
Jenscare Scientific Achieves Milestone with First LuX-Valve Plus Implantation in Brazil
•
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in Ningbo, China, has announced the successful completion of the first clinical implantation surgery using its transjugular tricuspid valve replacement product, LuX-Valve Plus, in Brazil. This milestone marks a significant advancement for the company in the…
-
Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study
•
Jenscare Scientific Co., Ltd. (HKG: 9877), a Ningbo-based manufacturer of devices for structural heart disease, has released promising one-year results from a confirmatory study of its transcatheter tricuspid valve replacement system, LuX-Valve. The prospective, multi-center, single-arm study aimed to evaluate the safety and efficacy of the LuX-Valve in patients suffering…
-
Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System
•
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer based in Ningbo, has announced that its regulatory filing for the transcatheter artificial aortic valve system, Ken Valve, has been accepted into the priority review process by the National Medical Products Administration (NMPA). This marks a significant…
-
Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific
•
Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease solutions, has announced the successful completion of a series of paid compassionate use cases for its innovative transjugular tricuspid valve replacement product, LuX-Valve Plus, across multiple hospitals in the Asia-Pacific region. Clinical Success and Industry…
-
Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program
•
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that its in-house developed transcatheter tricuspid valve replacement system product has been included in the Total Product Life Cycle Advisory Program (TAP) of the US FDA. The program’s objective is to ensure that US patients have…
